Document is current
Any future updates will be listed below
-
Authors
Cunningham, Joseph M. https://orcid.org/0000-0002-1675-913X
Koytiger, Grigoriy
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
AlQuraishi, Mohammed https://orcid.org/0000-0001-6817-1322
-
Funding
Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (W911NF-14-1-0397)
United States Department of Defense | Defense Advanced Research Projects Agency (W911NF-14-1-0397)
United States Department of Defense | Defense Advanced Research Projects Agency (W911NF-14-1-0397)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54-CA225088)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54-CA225088)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54-CA225088)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P50-GM107618)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P50-GM107618)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P50-GM107618)
- License Information
-
More Information
Article History
Received: 20 May 2019
Accepted: 15 November 2019
First Online: 6 January 2020
Competing interests
: P.K.S. is a member of the SAB or Board of Directors of Merrimack Pharmaceutical, Glencoe Software, Applied Biomath and RareCyte Inc. and has equity in these companies. P.K.S. declares that none of these relationships are directly or indirectly related to the content of this manuscript.
